Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
218 Leser
Artikel bewerten:
(0)

Medbox Clients Lead the Way with Favorable Arizona Legal Ruling

Finanznachrichten News

HOLLYWOOD, Calif., July 31, 2013 /PRNewswire/ -- Medbox, Inc. (OTC Markets: MDBX) (www.medboxinc.com), a leader in providing industry specific consulting services and patented systems to the medical and retail industries, announced that its Arizona dispensary clients were just granted more time than initially allowed by state regulations to get their dispensaries up and running. Medbox's clients are lead plaintiffs in an injunction suit seeking extra time to open given legal and political challenges to the implementation of Arizona's Medical Marijuana Act. Other dispensaries later joined in the suit. Judge Randall Warner's ruling granting the plaintiffs' injunction request requires the Arizona Department of Health Services to renew the dispensaries' certificates for another year, and make new rules allowing dispensaries to apply to the agency for more time if needed, instead of coming back to Court.

"We knew our clients had been working hard to get their dispensaries open and operating, but some met with greater resistance than others in their local jurisdictions. Once we saw that problem unfolding, our instinct was to come to the aid of those clients who needed extra help. Our clients led the way in the injunction suit to get the state regulations changed," stated Vincent Mehdizadeh, Chief Operations Officer of Medbox, Inc. "We respect the work that ADHS did in making its rules initially. It became clear to us though that there were things that ADHS simply could not foresee. Holding diligent dispensary operators to a strict one-year time frame to get local jurisdiction approval was simply an undue burden on them. Going to court was the only way to get the legal relief that some of our clients needed."

Medbox was involved in Arizona's program at its very early stages, and submitted comments to ADHS during the rulemaking process.

"One of the things that distinguishes Medbox has been its commitment to the whole process from the agency rulemaking stage to helping clients get open and operating," Dr. Bruce Bedrick,Medbox CEO stated. "We are very pleased by Judge Warner's ruling and are gratified that it will help our clients move closer to their goals."

About Medbox, Inc:

Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Arizona, Connecticut, Massachusetts, Tokyo, London and Toronto, and has their corporate headquarters in Los Angeles.

Medbox provides their patented systems, software and consulting services to pharmacies, dispensaries, urgent care centers, drug rehab clinics, hospitals, prison systems, hospice facilities, and medical groups worldwide.

Medbox, Inc. is a publicly traded company, and is quoted on the OTC Markets, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online towww.medboxinc.com.

Forward-Looking Statements:The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry, political conditions and economic conditions in the states considering such legislation. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.

SOURCE Medbox, Inc.

© 2013 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.